Butterfly Network has staged one of the more violent short-term rallies in the health care equipment space, gaining 56% in a single week and 132% over the past month to close at $8.90 — yet the short sellers have barely flinched, and insiders were selling heavily into a much lower price just two weeks ago.
The price move is the story here, and the positioning data around it raises more questions than it answers. Short interest has barely moved — 11.1% of free float, down less than 1% on the week despite the stock nearly doubling in a month. That is a meaningful level of short conviction; with roughly 25.2 million shares short, there has been no rush to cover. The borrow market offers little drama: cost to borrow is a near-trivial 0.50%, and availability is wide open at 388% — meaning nearly four shares are available to lend for every one currently borrowed. The 52-week availability low was 74%, so today's reading represents an exceptionally loose lending market. Shorts are not being squeezed out; they are choosing to hold. Options traders tell a similar story. The put/call ratio has dropped to 0.18, slightly below its 20-day average and 1.5 standard deviations beneath it, suggesting the options market is tilted heavily toward calls. That is consistent with momentum-chasing rather than hedging — but the low PCR is also well inside the 52-week low of 0.05, so this is not an extreme reading. Overall, positioning looks like a crowded bull side meeting a stubborn short base, with neither borrow pressure nor options extremes adding urgency to the standoff.
The Street's analyst community has been constructive but cautious, and notably, price targets have been overtaken by events. The most recent analyst actions — Freedom Broker and TD Cowen both raising targets in late February and early March to $5.50 and $6.00 respectively — now sit well below the current price of $8.90. The highest recorded target in the recent changes is $6.00. With the stock trading 48% above the mean price target of $7.06, the math tells an uncomfortable story: either the Street has not caught up with a genuine re-rating, or the move has run well ahead of fundamental justification. The forward EPS momentum factor score of 18 (out of 100) and the deeply negative PE and EV/EBITDA multiples point firmly at the latter — this remains a loss-making business, with the stock now trading at 3.6x book and a negative earnings yield. The one bright spot in the factor scores is the 12-month forward EPS growth rank, which sits in the 98th percentile, suggesting analysts do see a meaningful inflection coming — just not yet.
The insider picture deserves a close look, and it complicates the bullish narrative considerably. Every recent insider transaction has been a sale. Steve Cashman, a C-suite officer, sold nearly 400,000 shares across two transactions in early June at prices of $4.66 and $4.96 — collecting roughly $1.9 million at levels that now look like a significant discount to market. CEO Joseph DeVivo sold 482,000 shares in March at $3.71. The Chief Accounting Officer sold in May at $4.75. Net insider disposals over the past 90 days total around 859,000 shares, worth approximately $4.2 million — all conducted when the stock was trading between $3.70 and $5.22. None of the recent selling appears to have been ahead of a known catalyst; the next earnings event is not until July 31.
The earnings history adds one more data point worth tracking. The two most recent prints each produced a modest positive reaction on the day — around 1–10% — but both were followed by sharp five-day reversals of roughly 13%. A pattern of strong-day-then-fade is worth noting in a name that has just posted a 132% one-month move, with Q1 results on June 18 now in the rearview and Q2 results scheduled for July 31.
What to watch: whether short sellers begin to cover in size as the stock trades above every recent analyst price target, and whether any analyst updates their target in the days ahead to account for a stock that has, in a matter of weeks, moved into entirely uncharted territory relative to current Street estimates.
See the live data behind this article on ORTEX.
Open BFLY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
